Literature DB >> 9401667

Dexmedetomidine alleviates ethanol withdrawal symptoms in the rat.

P Riihioja1, P Jaatinen, H Oksanen, A Haapalinna, E Heinonen, A Hervonen.   

Abstract

The effect of dexmedetomidine, a selective alpha 2-adrenoceptor agonist, on ethanol withdrawal symptoms was studied in chronically ethanol-fed rats. After a 4-day ethanol intoxication period the rats were given s.c. injections of dexmedetomidine (3, 10, or 30 micrograms/kg) or saline (control group) at 10, 16, 22, and 39 h after the last dose of ethanol. The severity of ethanol withdrawal symptoms (rigidity, tremor, irritability, hypoactivity) was rated up to 58 h, blind to the treatments. The results showed that dexmedetomidine at doses 10 and 30 micrograms/kg significantly diminished the severity of the ethanol withdrawal reaction as measured by the sum score of the three most specific withdrawal signs (rigidity, tremor, and irritability). Dexmedetomidine at 10 micrograms/kg was the most effective dose, especially in the latter half of the withdrawal period (23-58 h after last dose of ethanol). The results suggest that dexmedetomidine in the treatment of ethanol withdrawal symptoms should be further studied.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9401667     DOI: 10.1016/s0741-8329(97)00044-x

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  11 in total

1.  Current approaches to the recognition and treatment of alcohol withdrawal and delirium tremens: "old wine in new bottles" or "new wine in old bottles".

Authors:  Theodore A Stern; Anne F Gross; Thomas W Stern; Shamim H Nejad; Jose R Maldonado
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 3.  Is it prime time for alpha2-adrenocepter agonists in the treatment of withdrawal syndromes?

Authors:  Timothy E Albertson; James Chenoweth; Jonathan Ford; Kelly Owen; Mark E Sutter
Journal:  J Med Toxicol       Date:  2014-12

Review 4.  A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.

Authors:  R L Bell; S Hauser; Z A Rodd; T Liang; Y Sari; J McClintick; S Rahman; E A Engleman
Journal:  Int Rev Neurobiol       Date:  2016-03-21       Impact factor: 3.230

Review 5.  Dexmedetomidine: applications for the pediatric patient with congenital heart disease.

Authors:  Joseph D Tobias; Punkaj Gupta; Aymen Naguib; Andrew R Yates
Journal:  Pediatr Cardiol       Date:  2011-09-10       Impact factor: 1.655

6.  Dexmedetomidine controls agitation and facilitates reliable, serial neurological examinations in a non-intubated patient with traumatic brain injury.

Authors:  Julin F Tang; Po-Liang Chen; Eric J Tang; Todd A May; Shirley I Stiver
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

Review 7.  Stress modulation of drug self-administration: implications for addiction comorbidity with post-traumatic stress disorder.

Authors:  Marian L Logrip; Eric P Zorrilla; George F Koob
Journal:  Neuropharmacology       Date:  2011-07-19       Impact factor: 5.250

8.  alpha1-noradrenergic receptor antagonism blocks dependence-induced increases in responding for ethanol.

Authors:  Brendan M Walker; Dennis D Rasmussen; Murray A Raskind; George F Koob
Journal:  Alcohol       Date:  2008-03       Impact factor: 2.405

Review 9.  Dexmedetomidine: a review of applications for cardiac surgery during perioperative period.

Authors:  Xiaoyu Zhang; Xuan Zhao; Yingwei Wang
Journal:  J Anesth       Date:  2014-06-10       Impact factor: 2.078

Review 10.  Dexmedetomidine for the treatment of alcohol withdrawal syndrome: rationale and current status of research.

Authors:  Andrew J Muzyk; Suzanne Kerns; Scott Brudney; Jane P Gagliardi
Journal:  CNS Drugs       Date:  2013-11       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.